This company has been acquired
Opiant Pharmaceuticals Management
Management criteria checks 2/4
Opiant Pharmaceuticals' CEO is Roger Crystal, appointed in Sep 2009, has a tenure of 13.5 years. total yearly compensation is $1.48M, comprised of 42.9% salary and 57.1% bonuses, including company stock and options. directly owns 0.64% of the company’s shares, worth $695.26K. The average tenure of the management team and the board of directors is 5.5 years and 6.8 years respectively.
Key information
Roger Crystal
Chief executive officer
US$1.5m
Total compensation
| CEO salary percentage | 42.9% |
| CEO tenure | 13.5yrs |
| CEO ownership | 0.6% |
| Management average tenure | 5.5yrs |
| Board average tenure | 6.8yrs |
Recent management updates
Recent updates
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Analysts Just Slashed This Year's Estimates
Aug 13
Opiant awarded additional $2.1M from BARDA for its nasal opioid overdose treatment
Aug 08Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Shares Could Be 47% Below Their Intrinsic Value Estimate
Aug 05Analysts Just Made A Major Revision To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Revenue Forecasts
Mar 21Opiant Pharmaceuticals (NASDAQ:OPNT) Is Posting Healthy Earnings, But It Is Not All Good News
Nov 19These 4 Measures Indicate That Opiant Pharmaceuticals (NASDAQ:OPNT) Is Using Debt Reasonably Well
Nov 17Opiant Pharmaceuticals: Assessing Recent Insider Buying
Sep 19Party Time: Brokers Just Made Major Increases To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Earnings Forecasts
Aug 07Increases to CEO Compensation Might Be Put On Hold For Now at Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)
Jun 09The Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Yearly Results Are Out And Analysts Have Published New Forecasts
Mar 06News Flash: Analysts Just Made A Substantial Upgrade To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Forecasts
Mar 05Opiant Pharmaceuticals'(NASDAQ:OPNT) Share Price Is Down 41% Over The Past Three Years.
Jan 27Opiant Pharma secures additional BARDA grant of $3.5M for OPNT003
Dec 14Opiant Pharmaceuticals receives $50M in convertible debt financing
Dec 10CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2022 | n/a | n/a | -US$33m |
| Jun 30 2022 | n/a | n/a | -US$20m |
| Mar 31 2022 | n/a | n/a | -US$6m |
| Dec 31 2021 | US$1m | US$635k | US$3m |
| Sep 30 2021 | n/a | n/a | US$2m |
| Jun 30 2021 | n/a | n/a | -US$1m |
| Mar 31 2021 | n/a | n/a | -US$3m |
| Dec 31 2020 | US$1m | US$610k | -US$2m |
| Sep 30 2020 | n/a | n/a | -US$108k |
| Jun 30 2020 | n/a | n/a | US$10m |
| Mar 31 2020 | n/a | n/a | US$12m |
| Dec 31 2019 | US$1m | US$592k | US$12m |
| Sep 30 2019 | n/a | n/a | US$988k |
| Jun 30 2019 | n/a | n/a | -US$11m |
| Mar 31 2019 | n/a | n/a | -US$14m |
| Dec 31 2018 | US$865k | US$574k | -US$21m |
| Sep 30 2018 | n/a | n/a | -US$2m |
| Jun 30 2018 | n/a | n/a | -US$5m |
| Mar 31 2018 | n/a | n/a | -US$3m |
| Dec 31 2017 | n/a | n/a | US$3m |
| Oct 31 2017 | n/a | n/a | US$2m |
| Jul 31 2017 | US$1m | US$568k | US$7m |
| Apr 30 2017 | n/a | n/a | US$6m |
| Jan 31 2017 | n/a | n/a | US$9m |
| Oct 31 2016 | n/a | n/a | US$3m |
| Jul 31 2016 | US$5m | US$616k | -US$8m |
Compensation vs Market: Roger's total compensation ($USD1.48M) is above average for companies of similar size in the US market ($USD738.70K).
Compensation vs Earnings: Roger's compensation has increased whilst the company is unprofitable.
CEO
Roger Crystal (46 yo)
13.5yrs
Tenure
US$1,477,846
Compensation
Dr. Roger Crystal, M.D., has been an Independent Director of Mind Medicine (MindMed) Inc. since August 11, 2022. Dr. Crystal has been the Chief Executive Officer of Opiant Pharmaceuticals, Inc. since Septe...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 13.5yrs | US$1.48m | 0.64% $ 695.3k | |
| Chief Financial Officer | 5.5yrs | US$786.67k | 0.43% $ 464.9k | |
| Chief Scientific Officer | 6.1yrs | US$800.11k | 0.19% $ 202.6k | |
| Vice President of Communications & Investor Relations | no data | no data | no data | |
| EVP Corporate Development & General Counsel | 2.6yrs | no data | 0.34% $ 369.9k | |
| Chief Development Officer | no data | no data | 0.36% $ 387.2k | |
| Chief Commercial Officer | 1.7yrs | no data | 0.13% $ 137.7k |
5.5yrs
Average Tenure
57.5yo
Average Age
Experienced Management: OPNT's management team is seasoned and experienced (5.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 13.5yrs | US$1.48m | 0.64% $ 695.3k | |
| Independent Director | 12.3yrs | US$42.70k | 1.14% $ 1.2m | |
| Independent Director | 6.3yrs | US$113.70k | 0.20% $ 214.2k | |
| Independent Chairman | 4.4yrs | US$137.20k | 1.02% $ 1.1m | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Independent Director | 6.8yrs | US$109.70k | 0.50% $ 540.6k | |
| Chairwoman of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Independent Director | 6.8yrs | US$103.70k | 0.41% $ 440.7k | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data |
6.8yrs
Average Tenure
60yo
Average Age
Experienced Board: OPNT's board of directors are considered experienced (6.8 years average tenure).